

Emflaza® (deflazacort) – First-time generic

- On February 9, 2024, <u>Aurobindo launched</u> an <u>AB-rated</u> generic version of PTC Therapeutics' <u>Emflaza (deflazacort)</u> tablets.
 - Emflaza is also available as a brand oral suspension.
- Emflaza is approved for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older.
 - Aurobindo's generic Emflaza tablets are approved for the same indication in patients 5 years of age and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.